# Timothy Low

> Timothy Low is a venture - series unknown investor at Pavilion Capital backing Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pavilion Capital](https://shizune.co/investors/profile/pavilion-capital)
- Total investments: 4
- Last investment: Jun 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://sg.linkedin.com/in/timothylowso

Timothy Low is a Healthcare Investment Consultant at Pavilion Capital International. He Attended National University of Singapore.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 25% |
| Biotechnology | 1 | 25% |
| Pharmaceutical | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M | Venture - Series Unknown | Feb 25, 2020 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M | Venture - Series Unknown | Feb 25, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 4 deals together
- [HBL Hadasit Bio Holdings](https://shizune.co/investors/profile/hbl-hadasit-bio-holdings) — VC Fund, 4 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 4 deals together
- [Oriella Ltd.](https://shizune.co/investors/profile/oriella-ltd) — VC Fund, 4 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together

## About Pavilion Capital

VC Fund · New York, United States

Pavilion Capital Partners is a growth-oriented private equity investor. It provides capital and strategic support to companies in the United States and Asia. In particular, the focus is on industries experiencing high growth due to globalization, technology, or demographic trends. It actively works with company founders/management to assistin strategic initiatives, mergers and acquisitions, and eventual liquidity. The pavilion is partnered with family offices and private equity funds and is based in New York City.

3 contacts available at Pavilion Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Timothy Low | Healthcare Investment Consultant | https://shizune.co/investors/profile/timothy-low-78c7 |
| Jean-Francois Perrault | Founder | https://shizune.co/investors/profile/jean-francois-perrault-962f |
| Tow Heng Tan | CEO | https://shizune.co/investors/profile/tow-heng-tan |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Timothy Low invest in?

Timothy Low invests primarily in Medical, Biotechnology and Pharmaceutical startups, most often at Venture - Series Unknown stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Timothy Low last invest?

The most recent investment recorded for Timothy Low closed in Jun 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co